心臟衰竭药物市场（按药物类别、心臟衰竭类型、给药方法、最终用户和分销管道划分）—2025-2032 年全球预测

预计到 2032 年心臟衰竭药物市场规模将成长至 602.3 亿美元，复合年增长率为 10.98%。

主要市场统计数据
基准年2024年	261.6亿美元
预计2025年	291亿美元
预测年份：2032年	602.3亿美元
复合年增长率（%）	10.98%

现代心臟衰竭药物的简洁、情境化框架强调了临床重点、护理途径和相关人员的决策工具

心臟衰竭药物处于临床紧迫性、不断发展的分子科学和不断变化的医疗服务模式的关键交叉点。本执行摘要总结了临床医生、付款人、行业领导者和政策制定者的当前形势，重点介绍了对患者预后最关键的治疗层级和护理途径。引言部分将最新的治疗方法进展置于不断变化的临床指南和对慢性病管理日益关注的背景下，其余分析则组装于实际意义而非抽象的预测。

本文重点介绍了现有药物类别的渐进式创新，以及新药物和辅助治疗策略如何重新定义治疗流程。此外，本文也强调了影响日常实践中采用这些药物的实际因素，例如给药途径、急性和慢性治疗的差异，以及诊所、医院和家庭环境。透过将研究内容与现实世界的决策驱动因素连结起来，本节将引导读者更深入分析未来前景、关税影响、市场区隔洞察以及区域动态。

本书始终在临床细节和商业性实用性之间保持平衡。引言并非试图逐一列举每一项进展，而是重点阐述了决定治疗价值、相关人员优先考虑的问题，以及各机构应如何调整运作以抓住心臟衰竭治疗领域的新机会。

深入分析药理学创新、复杂的表型分析和不断发展的医疗服务模式如何共同重塑治疗策略和获取途径

技术创新、指南演变和医疗服务重新设计等因素共同作用，正在改变心臟衰竭治疗格局。药理学的进步正在扩展临床医生的套件，使其不再局限于传统的血流动力学药物，而是涵盖针对代谢、发炎和肾心轴的药物。因此，ACE抑制剂、ARB、 β阻断剂、利尿剂、MRAs和SGLT2抑制剂等既定类别正在更精细的治疗方案中重新评估，并相应地强调联合策略和给药顺序。

同时，诊断的改进和对錶型异质性的更深入理解，集中在区分射血分数保留型和降低型亚型以及急性和慢性疾病。这些临床定义影响治疗方法选择、监测强度和预期结果。给药偏好也在发生变化，与住院模式和扩大居家照护相关的口服慢性方案与间歇性或急性静脉注射之间的相互作用也在发生变化。

从营运角度来看，分销和获取管道正在同步转型。虽然线下通路（主要是医院和零售药局）对于急诊和专科配药仍然至关重要，但线上履约和远端医疗医疗处方在慢性病用药的连续性方面正日益受到青睐。终端使用者诊所、居家医疗机构和医院正在适应新的用药启动、剂量调整和监测方案，重塑了实证医学转化为实践的方式。这些累积效应导致治疗方法选择、护理环境和获取机制的格局迅速演变，需要在临床、商业和政策领域制定协调一致的策略。

对近期关税主导的供应链效应及其对采购、分销和治疗准入框架的营运影响全面评估。

美国近期的关税变化对心臟衰竭治疗领域的製造商、经销商和下游医疗保健提供者产生了多重影响。关税变化将影响整个供应链的成本结构，影响原料药药物成分、成品製剂以及用于监测和给药的设备相关产品的到岸成本。这些压力可能会改变与医院系统和药房网路的合约动态，并可能促使公共和私人付款人重新评估筹资策略。

营运连锁反应延伸至通路经济。医院药房采购惯例、零售药房备货决策以及线上分销协议都对关税调整引起的投入成本波动敏感。为此，製造商可能会在地采购、与其他供应商合作或重新协商分销条款，以保护利润率并确保患者获得药品的连续性。同样，采用基于价值的支付安排的医疗保健提供者可能会重新评估处方和护理途径，以在维持临床标准的同时管理总护理成本。

临床医生和卫生系统领导者需要在短期营运调整与长期韧性措施之间取得平衡。这需要供应链、药房和临床领导层之间更紧密的合作；加强对潜在供应中断的情境规划；并与付款人进行策略对话，以确保患者能够获得指南推荐的疗法。最终，关税带来的成本压力将成为整个医疗服务生态系统中更一体化的采购和治疗管理实践的催化剂。

透过多维细分洞察来引导您的目标策略，协调药物类别、表型差异、给药途径、治疗环境和分销架构

细分提供了将治疗差异转化为可操作策略所需的分析框架。从药物类别来看，治疗方法选择差异显着：ACE 抑制剂和 ARB 仍然是神经激素调节的基石， β阻断剂可缓解交感神经兴奋过度，利尿剂可管理有症状患者的体液平衡，MRA 有助于拮抗剂可缓解交感神经兴奋过度，利尿剂可管理有症状患者的体液平衡，MRA 有助于拮抗剂抗盐皮质激素，而 SGLT2 抑製剂则超越了传统的药物类别界限，提供代谢和肾臟/心臟益处。这些类别层面的差异直接影响临床路径和商业性定位。

依心臟衰竭类型分类可进一步完善决策。射血分数保留和降低在生物学和操作上是截然不同的领域，与慢性维持治疗相比，在急性发作期间，每个领域都需要不同的启动、调整和监测策略。给药方式引入了一条正交的分化轴：静脉注射在急性住院治疗中占主导地位，而口服方案是慢性门诊病人治疗的基础，从而实现了诊所和居家照护环境中的连续性。

将终端使用者细分为诊所、家庭护理机构和医院，可以反映治疗启动和维持地点的实际情况，从而影响患者援助计划、依从性干预措施和监测基础设施。分销管道的细微差别——线下与线上，以及医院与零售药局之间的线下——会影响治疗时间、库存管理和患者便利性。将这些相互交叉的细分维度结合起来，可以提供多维视角，支持有针对性的临床通讯协定、差异化的商业策略以及在物流和患者支持方面的商业投资。

区域动态和医疗保健系统特征决定了全球市场在治疗方法采用、报销途径和护理服务方面的差异

区域动态对全球心臟衰竭领域的治疗方法采用、报销和交付方式有重大影响。在美洲，付款人结构、整合的交付网络以及专科中心的集中度决定了方案的快速采用，为专科医生的分布和医院主导的治疗启动创造了途径。私人和公共付款人模式的广度也影响报销谈判和处方集的布局，从而影响治疗价值的体现。

在欧洲、中东和非洲，法律规范、资金筹措机制和临床基础设施的差异导致了医疗服务取得模式的不平衡。国家卫生系统和区域采购机构通常优先考虑成本效益和治疗结果，并强调真实世界证据的产生和基于结果的合约签订。诊断能力和专科护理可近性的差异可能会改变诊所治疗启动和医院管理之间的平衡。

亚太地区既有拥有先进三级医疗服务的大城市，也有受物流和基础设施限制的广大地区。这种多样性影响了口服慢性病治疗方案的采用以及对急性住院治疗的依赖，从而提升了数位医疗和远端医疗在填补医疗缺口方面的作用。在每个地区，当地监管的细微差别、供应链的稳健性以及支付方的期望都将决定治疗创新如何转化为可衡量的临床影响。

整合科学差异化、证据生成和商业伙伴关係以支持治疗方法采用的策略性企业优先事项和营运手册

公司策略日益取决于其如何有效地将科学差异化与整体医疗保健执行相结合。领先的研发和商业机构正将其研发、证据生成和生命週期管理重点放在化合物和组合上，以满足射血分数保留和降低患者群体中尚未满足的需求。策略重点包括证明临床效用、阐明在併发症族群中的安全性，以及产生可操作的证据以支持其在常规实践中的应用。

在商业性方面，各公司正在优化产品上市顺序和通路伙伴关係，以管理住院和门诊病人维护之间的过渡。与医院系统、专科药房和居家照护机构的合作有助于确保启动途径的畅通，确保出院后过渡期的连续性，并支持依从性计划。对真实世界证据平台和病患监测技术的投资，增强了与付款人和整合交付网路进行谈判的价值提案。

在营运方面，企业正在完善其供应链策略，以降低关税和采购风险，增强与临床使用模式相关的预测模型，并制定适合不同区域报销环境的定价方法。与数位医疗服务提供者和诊断公司的伙伴关係日益普遍，将治疗性介入与监测和依从性解决方案相结合，以改善疗效并支持长期产品差异化。

为开发商、付款人和供应商提供切实可行的优先行动，以加强临床和商业途径的可及性、证据完整性和供应弹性

产业领导者可以采取具体措施，提升心臟衰竭治疗的可近性、临床疗效和商业性韧性。首先，将临床开发和核准后证据项目与对支付方和医疗保健系统至关重要的可操作终点（例如避免住院和功能状态）相结合，同时开展试验，确保其能够捕捉射血分数保留和降低的患者群体相关的异质性患者表型。其次，设计衔接住院和门诊病人的上市和商业化计划，并与医院药房团队、诊所网路和居家照护提供者协调，制定清晰的启动和交接通讯协定。

此外，优先考虑采购弹性，并透过多元化供应商网路和探索关键投入的近岸外包方案来降低关税波动的风险。投资支持药物依从性和早期发现脱抑制的数位化和远端监控工具，提高临床价值并降低下游成本。积极与付款人合作，制定基于结果的合约机制，使报销与实际治疗结果保持一致。

最后，我们透过将证据产生和定价方法与当地监管和报销环境结合，强化区域策略。我们组成跨职能团队，整合临床、监管、报销和供应链专业知识，执行复杂的上市和生命週期倡议。这些行动帮助领导者将治疗前景转化为持续的临床和商业性影响，同时确保患者在不同医疗环境中都能获得治疗。

强大的混合方法研究设计结合了领先临床医生的意见、主题文献的综合和情境分析，确保了可操作和可辩护的见解

本研究采用混合方法，旨在产生严谨可行的洞见，将临床细节与商业性现实连结起来。主要的定性输入包括对医院系统、诊所和居家照护机构的循环系统、心臟衰竭护士、药房主任和采购负责人进行结构化访谈，收集关于治疗方法选择、启动途径和依从性挑战的第一手观点。这些一线洞见与二次研究相辅相成，二次研究使用同行评审的临床文献、监管指南和公开的组织报告来解释临床有效性、安全性和指南的演变。

分析方法包括跨治疗层级和护理路径整合、针对射血分数保留和降低人群的表型特异性临床映射，以及情境分析，以评估营运对供应链变数（例如关税变化）的反应。透过案例研究研究和供应链映射练习，评估剂型和分销管道的动态，揭示医院药房、零售药房和线上履约管道中的限制和推动因素。区域分析整合了美洲、欧洲、中东和非洲以及亚太地区的监管和报销考量，揭示了实施的实际意义。

研究结果将跨资讯来源进行三角检验，以确保内部一致性和实际相关性。当已发表数据稀缺或快速发展的临床证据可能改变治疗定位时，我们会承认其局限性，并强调可随着新的临床和操作数据的出现而更新的适应性策略。

综合临床、营运和社区主题，强调将治疗方法进展转化为持续患者利益的实用途径

摘要，心臟衰竭治疗市场格局的特征是临床进展显着且摘要复杂。如今，治疗方法差异已超越传统的血流动力学标靶药物，涵盖改善肾臟和代谢功能的药物，因此需要更细緻的临床决策路径，将表型、严重程度和合併症纳入考量。这些科学进步与不断变化的医疗服务模式交织在一起，诊所、医院和居家医疗在启动、调整和长期管理方面各自发挥不同的作用。

同时，线下医院和零售药局的履约，正在塑造分销和采购格局，需要製定协调一致的策略来维护药品的可及性并确保医疗服务的连续性。关税和供应链压力凸显了多元化采购以及临床、采购和报销相关人员之间更紧密合作的必要性。美洲、欧洲、中东和非洲以及亚太地区的区域差异进一步凸显了针对每个地区制定客製化证据和定价策略的重要性。

最终，如果相关人员将临床差异化与严谨的营运（例如证据生成、供应弹性和付款人参与）结合，将最有能力将治疗进展转化为患者疗效的可衡量改善。有针对性的证据投资、跨医疗机构的伙伴关係以及积极主动的供应链管理，将把潜力转化为持续的临床效益。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• SGLT2抑制剂的采用对心臟衰竭住院率和付款人策略的影响
• 透过远端监控和远端医疗平台整合减少心臟衰竭管理中的再入院率
• 改善HFrEF患者收缩功能的心肌肌凝蛋白活化剂开发平臺
• 新型肽基脑啡肽酶抑制剂在治疗郁血性心臟衰竭的市场进入挑战
• 生物标记和个人化医疗在指导最佳心臟衰竭治疗中的新兴作用
• 生物技术公司与数位医疗公司建立策略合作伙伴关係，用于心臟衰竭患者的远端管理
• 不断变化的监管格局和创新心臟衰竭药物及诊断的快速核准
• 以价值为基础的照护模式对心臟衰竭药物处方模式的经济影响

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第 8 章心臟衰竭药物市场（依药物类别）

• 血管紧张素转换酶抑制剂
• ARB
• β受体阻断剂
• 利尿剂
• MRA
• SGLT2抑制剂

第九章心臟衰竭药物市场（按心臟衰竭类型）

• 射血分数保留
  • 急性
  • 慢性的
• 射血分数降低型
  • 急性
  • 慢性的

第 10 章心臟衰竭药物市场依给药方式

• 静脉
• 口服

第 11 章心臟衰竭药物市场（依最终用户）

• 诊所
• 居家医疗
• 医院

第 12 章心臟衰竭药物市场（依分销管道）

• 离线
  • 医院药房
  • 零售药局
• 在线的

第十三章心臟衰竭药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章心臟衰竭药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国心臟衰竭药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Novartis International AG
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Laboratoires Servier
  • Boston Scientific Corporation
  • Amgen Inc.
  • Cardurion Pharmaceuticals

The Heart Failure Therapeutics Market is projected to grow by USD 60.23 billion at a CAGR of 10.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 26.16 billion
Estimated Year [2025]	USD 29.10 billion
Forecast Year [2032]	USD 60.23 billion
CAGR (%)	10.98%

Concise contextual framing of contemporary heart failure therapeutics highlighting clinical priorities, care pathways, and operational decision levers for stakeholders

Heart failure therapeutics occupy a pivotal intersection of clinical urgency, evolving molecular science, and shifting care delivery models. This executive summary synthesizes the contemporary landscape for clinicians, payers, industry leaders, and policy makers, emphasizing the therapeutic classes and care pathways that matter most in shaping patient outcomes. The introduction situates recent therapeutic advances against a backdrop of changing clinical guidelines and heightened attention to chronic disease management, framing the rest of the analysis around practical implications rather than abstract projections.

The discussion foregrounds how incremental innovations across established drug classes, alongside newer agents and adjunctive care strategies, are redefining treatment algorithms. It emphasizes the practical considerations that influence adoption in routine care, such as route of administration, acute versus chronic management distinctions, and where care is delivered-clinic, hospital, or home settings. By anchoring the narrative to real-world decision levers, this section prepares the reader for deeper analysis of landscape shifts, tariff impacts, segmentation insights, and regional dynamics that follow.

Throughout, the tone balances clinical nuance and commercial pragmatism. The introduction does not seek to catalog every development but rather to clarify the themes that determine therapeutic value, stakeholder priorities, and the operational adjustments organizations will need to make to capitalize on emerging opportunities in heart failure care.

Detailed analysis of how pharmacologic innovation, refined phenotyping, and evolving care delivery models are jointly reshaping therapeutic strategies and access pathways

The therapeutic landscape for heart failure is undergoing transformative shifts driven by a confluence of innovation, guideline evolution, and care delivery redesign. Advances in pharmacology are broadening the clinician's toolkit beyond traditional modulators of hemodynamics to include agents that target metabolic, inflammatory, and renal-cardiac axes. As a result, established categories such as ACE inhibitors, ARBs, beta blockers, diuretics, MRAs, and SGLT2 inhibitors are being re-evaluated within more finely stratified treatment pathways, while combination strategies and sequencing considerations gain prominence.

Concurrently, diagnostic refinements and a deeper understanding of phenotype heterogeneity have sharpened focus on preserved versus reduced ejection fraction subtypes, and on acute as distinct from chronic management. These clinical delineations affect therapeutic selection, monitoring intensity, and expected outcomes. Mode-of-administration preferences are also shifting, as oral chronic regimens interact with intermittent or acute intravenous interventions tied to hospitalization patterns and home-based care expansion.

Operationally, distribution and access channels show parallel transformation. Offline channels anchored in hospital and retail pharmacies remain essential for acute care and specialty dispensing, while online fulfillment and telehealth-enabled prescribing are gaining traction for chronic medication continuity. End-user dynamics-clinics, home care settings, and hospitals-are adapting to new protocols for initiation, titration, and monitoring, reshaping how evidence translates into practice. The cumulative effect is a landscape where therapeutic choice, care setting, and access mechanisms co-evolve rapidly, demanding coordinated strategies across clinical, commercial, and policy domains.

Comprehensive appraisal of recent tariff-driven supply chain effects and their operational consequences for procurement, distribution, and therapeutic access frameworks

Recent tariff developments in the United States have introduced layered implications for manufacturers, distributors, and downstream care providers operating in the heart failure therapeutics space. Tariff changes influence cost structures across the supply chain, affecting the landed cost of active pharmaceutical ingredients, finished dose formulations, and device-adjacent products used in monitoring and administration. These pressures can alter contracting dynamics with hospital systems and pharmacy networks and may prompt re-evaluation of procurement strategies for both public and private payers.

The operational ripple effects extend to channel economics. Hospital pharmacy procurement practices, retail pharmacy stocking decisions, and online distribution agreements are sensitive to input-cost variability created by tariff adjustments. In response, manufacturers may pursue localized sourcing, alternative supplier partnerships, or renegotiated distribution terms to preserve margin and ensure uninterrupted patient access. Similarly, providers under value-based payment arrangements might reassess formularies and therapeutic pathways to manage total cost of care while maintaining clinical standards.

Clinicians and health system leaders will need to balance short-term operational adjustments with long-term resilience measures. This entails closer coordination among supply chain, pharmacy, and clinical leadership, increased scenario planning for potential supply disruptions, and strategic dialogue with payers to preserve access to guideline-recommended therapies. Ultimately, tariff-induced cost pressures act as a catalyst for more integrated procurement and therapeutic stewardship practices across the delivery ecosystem.

Multidimensional segmentation insights that reconcile drug class, phenotype distinctions, administration routes, care settings, and distribution architectures to inform targeted strategies

Segmentation provides the analytical scaffolding needed to translate therapeutic nuance into actionable strategy. When viewed through the lens of drug class differentiation, therapeutic choice varies markedly: ACE inhibitors and ARBs remain foundational for neurohormonal modulation, beta blockers address sympathetic overactivity, diuretics manage fluid balance in symptomatic patients, MRAs contribute to mineralocorticoid antagonism, and SGLT2 inhibitors offer metabolic and renal-cardiac benefits that cross traditional class boundaries. These class-level distinctions directly shape clinical pathways and commercial positioning.

Disaggregating by heart failure type further refines decision-making. Preserved ejection fraction and reduced ejection fraction represent biologically and operationally distinct domains; within each, acute episodes necessitate different initiation, titration, and monitoring strategies compared with chronic maintenance care. Mode of administration introduces an orthogonal axis of differentiation: intravenous therapy dominates the acute, inpatient context, while oral regimens support chronic outpatient management and enable continuity across clinic and home care settings.

End-user segmentation-clinics, home care settings, and hospitals-captures the practical realities of where therapies are initiated and maintained, influencing patient support programs, adherence interventions, and monitoring infrastructure. Distribution channel nuances between offline and online channels, with offline further split into hospital and retail pharmacies, affect time-to-treatment, inventory management, and patient convenience. Together, these intersecting segmentation axes provide a multidimensional view that supports targeted clinical protocols, differentiated commercial strategies, and operational investments in logistics and patient support.

Regional dynamics and health system characteristics that shape therapeutic adoption, reimbursement pathways, and care delivery variations across global markets

Regional dynamics exert a powerful influence on how therapies are adopted, reimbursed, and delivered across the global heart failure landscape. In the Americas, payer structures, integrated delivery networks, and a high concentration of specialist centers shape rapid protocol adoption and create pathways for specialty distribution and hospital-led therapeutics initiation. The breadth of private and public payer models also affects reimbursement negotiations and formulary placements, with implications for how therapeutic value is demonstrated.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, funding mechanisms, and clinical infrastructure leads to variable uptake patterns. National health systems and regional procurement bodies often prioritize cost-effectiveness and therapeutic outcomes, which drives emphasis on real-world evidence generation and outcomes-based contracting. Differences in diagnostic capacity and access to specialty care can alter the balance between clinic-based initiation and hospital-centered management.

Asia-Pacific presents both large urban centers with advanced tertiary care and vast regions where access is constrained by logistics and infrastructure. This diversity influences the adoption of oral chronic regimens versus reliance on acute inpatient interventions, and it elevates the role of digital health and telemedicine in bridging care gaps. Across all regions, local regulatory nuance, supply-chain robustness, and payer expectations will determine how therapeutic innovations translate into measurable clinical impact.

Strategic corporate priorities and operational playbooks that integrate scientific differentiation, evidence generation, and distribution partnerships to support therapeutic adoption

Company strategies are increasingly defined by how effectively they align scientific differentiation with operational execution across the care continuum. Leading developers and commercial organizations are concentrating R&D, evidence generation, and lifecycle management around compounds and combinations that address unmet needs within preserved and reduced ejection fraction populations. Strategic priorities include demonstrating benefit in hard clinical outcomes, elucidating safety profiles across comorbid populations, and generating pragmatic evidence that supports adoption in routine practice.

On the commercial front, firms are optimizing launch sequencing and channel partnerships to manage the transition between inpatient initiation and outpatient maintenance. Collaboration with hospital systems, specialty pharmacies, and home care providers helps secure pathways for initiation, ensures continuity during post-discharge transitions, and supports adherence programs. Investments in real-world evidence platforms and patient monitoring technologies strengthen value propositions in negotiations with payers and integrated delivery networks.

Operationally, companies are also refining supply chain strategies to mitigate tariff and sourcing risks, enhancing forecasting models tied to clinical utilization patterns, and developing tailored pricing approaches for diverse regional reimbursement landscapes. Partnerships with digital health providers and diagnostics companies are increasingly common, aimed at connecting therapeutic interventions with monitoring and adherence solutions that improve outcomes and support long-term product differentiation.

Practical, prioritized actions for developers, payers, and providers to enhance access, evidence alignment, and supply resilience across clinical and commercial pathways

Industry leaders can take concrete steps to strengthen therapeutic access, clinical outcomes, and commercial resilience in heart failure care. First, align clinical development and post-approval evidence programs with the practical endpoints that matter to payers and health systems, such as hospitalization avoidance and functional status, while ensuring trials capture heterogeneous patient phenotypes relevant to preserved and reduced ejection fraction populations. Second, design launch and commercialization plans that bridge inpatient and outpatient settings, coordinating with hospital pharmacy teams, clinic networks, and home care providers to create clear initiation and handoff protocols.

Additionally, prioritize procurement resilience by diversifying supplier networks and exploring near-shoring options for critical inputs to reduce exposure to tariff volatility. Invest in digital and remote-monitoring tools that support adherence and early detection of decompensation, thereby enhancing clinical value and reducing downstream costs. Engage proactively with payers to develop outcome-based contracting mechanisms that align reimbursement with real-world therapeutic performance.

Finally, strengthen regional strategies by tailoring evidence generation and pricing approaches to local regulatory and reimbursement contexts. Build cross-functional teams that integrate clinical, regulatory, reimbursement, and supply chain expertise to execute complex market entry and lifecycle initiatives. These actions will help leaders convert therapeutic promise into sustained clinical and commercial impact while preserving access for patients across diverse care settings.

Robust mixed-methods research design combining frontline clinician input, targeted literature synthesis, and scenario analysis to ensure actionable and defensible insights

This research employs a mixed-methods approach designed to produce rigorous, actionable insights that bridge clinical nuance and commercial realities. Primary qualitative inputs include structured interviews with practicing cardiologists, heart failure nurses, pharmacy directors, and procurement leaders across hospital systems, clinics, and home care providers to capture firsthand perspectives on therapeutic choice, initiation pathways, and adherence challenges. These frontline insights are complemented by secondary research drawing on peer-reviewed clinical literature, regulatory guidance, and publicly available health system reports to contextualize clinical efficacy, safety, and guideline evolution.

Analytical methods include cross-sectional synthesis of therapeutic classes and care pathways, phenotype-specific clinical mapping for preserved and reduced ejection fraction populations, and scenario analysis to evaluate operational responses to supply-chain variables such as tariff changes. Mode-of-administration and distribution channel dynamics are assessed through case studies and supply-chain mapping exercises that highlight constraints and enablers across hospital pharmacies, retail pharmacies, and online fulfillment channels. Regional analysis integrates regulatory and reimbursement considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific to identify practical implications for adoption.

Throughout, findings have been triangulated across sources to ensure internal consistency and practical relevance. Limitations are acknowledged where public data are sparse or where rapidly evolving clinical evidence may alter therapeutic positioning, and recommendations emphasize adaptable strategies that can be updated as new clinical and operational data emerge.

Consolidated synthesis of clinical, operational, and regional themes underscoring pragmatic pathways to convert therapeutic advances into sustained patient benefit

In summary, the heart failure therapeutics landscape is characterized by substantive clinical evolution and operational complexity. Therapeutic differentiation now extends beyond traditional hemodynamic targets to include agents that deliver renal and metabolic benefits, necessitating more nuanced clinical decision pathways that account for phenotype, acuity, and comorbidity. These scientific advances intersect with shifting care delivery models, where clinics, hospitals, and home care settings each play distinct roles in initiation, titration, and long-term management.

At the same time, distribution and procurement dynamics-shaped by offline hospital and retail pharmacy practices as well as growing online fulfillment-require coordinated strategies to maintain access and ensure continuity of care. Tariff and supply-chain pressures underscore the need for diversified sourcing and tighter alignment between clinical, procurement, and reimbursement stakeholders. Regional variation across the Americas, Europe, Middle East & Africa, and Asia-Pacific further highlights the importance of locally tailored evidence and pricing strategies.

Ultimately, stakeholders who integrate clinical differentiation with operational rigor-aligning evidence generation, supply resilience, and payer engagement-will be best positioned to translate therapeutic advances into measurable improvements in patient outcomes. The path forward emphasizes pragmatism: targeted investments in evidence, partnerships across care settings, and proactive supply-chain management will convert potential into sustained clinical benefit.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Impact of SGLT2 inhibitor adoption on heart failure hospitalization rates and payer strategies
• 5.2. Integration of remote monitoring and telehealth platforms in heart failure management to reduce readmissions
• 5.3. Development pipeline advancements in cardiac myosin activators for improved systolic function in HFrEF patients
• 5.4. Market access challenges for novel peptide-based neprilysin inhibitors in congestive heart failure therapy
• 5.5. Emerging role of biomarkers and personalized medicine in guiding heart failure treatment optimization
• 5.6. Strategic partnerships between biotech and digital health companies for heart failure remote patient management
• 5.7. Regulatory landscape evolution and expedited approvals for innovative heart failure therapeutics and diagnostics
• 5.8. Economic implications of value-based care models on prescription patterns of heart failure drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure Therapeutics Market, by Drug Class

• 8.1. Ace Inhibitors
• 8.2. Arbs
• 8.3. Beta Blockers
• 8.4. Diuretics
• 8.5. Mras
• 8.6. SGLT2 Inhibitors

9. Heart Failure Therapeutics Market, by Heart Failure Type

• 9.1. Preserved Ejection Fraction
  • 9.1.1. Acute
  • 9.1.2. Chronic
• 9.2. Reduced Ejection Fraction
  • 9.2.1. Acute
  • 9.2.2. Chronic

10. Heart Failure Therapeutics Market, by Mode Of Administration

• 10.1. Intravenous
• 10.2. Oral

11. Heart Failure Therapeutics Market, by End User

• 11.1. Clinics
• 11.2. Home Care Settings
• 11.3. Hospitals

12. Heart Failure Therapeutics Market, by Distribution Channel

• 12.1. Offline
  • 12.1.1. Hospital Pharmacies
  • 12.1.2. Retail Pharmacies
• 12.2. Online

13. Heart Failure Therapeutics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Heart Failure Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Heart Failure Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Novartis International AG
  • 16.3.2. AstraZeneca PLC
  • 16.3.3. Boehringer Ingelheim International GmbH
  • 16.3.4. Pfizer Inc.
  • 16.3.5. Eli Lilly and Company
  • 16.3.6. Bayer AG
  • 16.3.7. Laboratoires Servier
  • 16.3.8. Boston Scientific Corporation
  • 16.3.9. Amgen Inc.
  • 16.3.10. Cardurion Pharmaceuticals

LIST OF FIGURES

• FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ARBS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MRAS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ACUTE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 189. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 190. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 239. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 242. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 243. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 244. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 257. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 260. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 261. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 262. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 275. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 277. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 279. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 295. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 298. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 299. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2024 (USD MILLION)
• TABLE 300. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY PRESERVED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY REDUCED EJECTION FRACTION, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN HEART FAILURE THERAPEU